Trusted for over 30 years, from local player to global market leader in pharmaceutical compounding.
Fagron was founded in Rotterdam (the Netherlands) in 1990. Through a continuous focus on innovation, quality and solution-oriented thinking, Fagron obtained market leadership in pharmaceutical compounding in the Netherlands in just 7 years.
Fagron’s successful strategy is focused on optimizing and innovating customized pharmaceutical care while widening therapeutic options for prescribers worldwide and improving patients’ quality of life. Its unique business model and the investments in innovation and product development resulted in the fact that Fagron is currently leading in pharmaceutical compounding and is active in 34 countries in Europe, the Americas, the Middle East, Africa, Asia and the Pacific.
Fagron products and innovations are sold to over 200,000 customers in over 60 countries around the world.
Innovative concepts, vehicles and formulations for pharmaceutical compounding that are developed by Fagron's R&D team, often in close cooperation with prescribers, pharmacies and universities.
Pharmaceutical raw materials, equipment and supplies (Fagron Lab) that pharmacists need in order to be able to prepare medication in the pharmacy.
Fagron Specialty Pharma Services
Customized medication or medication services prepared in Fagron’s sterile and non-sterile compounding facilities across Europe, North America, South America, and South Africa. In the US, learn more by visiting Fagron Sterile Services US.
Laboratory services focused on provideing specific pharmacogenetics and diagnostic molecular analysis for healthcare professionals. One patient. One treatment. Based on DNA. Learn more about this global project. In the US, visit GX Sciences, a Fagron company.
In the United States, Fagron, Inc., also known as Fagron Brands & Essentials, opperates production facilities out of St. Paul, Minnesota, and Texarkana, Texas, while Fagron's North American HQ is located in downtown Austin, Texas. The company has continued to grow through the years because of its innovation and ability to bring new products to the US compounding market.
As a forward-thinking pharmaceutical supplier, Fagron has been at the forefront of shaping industry leading standards in compounding for more than three decades. Fagron was founded in The Netherlands (1990). The aquisition of Gallipot (2010) supported Fagron's entrance into the US market, building on Gallipot's history as a US Food and Drug Administration-registered pharmaceutical supplier since 1980.
Fagron's reputation for quality and customer service continued to grow, leading to a loyal customer base and subsequent mergers and aquisitions including B&B Pharmaceuticals (2012), JCB Laboratories (2013), Humco (2018), and others.
Fagron adhers strictly to current Good Manufacturing Practices (cGMP). Bulk Pharmaceutical Ingredients (BPI) are purchased from reputable, registered, and validated manufacturers. Incoming BPIs are initially quarantined, then sampled and tested for identity, strength, quality, and purity in our Quality Control Laboratories, using methods as set forth in the applicable monographs of USP, NF, British Pharmacopoeia (BP), or European Pharmacopoeia (EP).
Repackaging is performed in our climate-monitored facility, then retested by Quality Control (QC) and reviewed by Quality Assurance (QA) before release to the market. Fagron, Inc. has been VAWD accredited since 2012, and is committed to preventing counterfeit, contaminated or diverted drugs from entering the United States drug supply. VAWD accreditation ensures that our distribution facility operates legitimately, is licensed in good standing, and is employing security and best practices for safely distributing prescription drugs.